Skip to content
AwardedHungaryServices

21 génes genomikai vizsg. (Oncotype DX) végzése

Published
Published 23 April 2026
Deadline
Closed 26 May 2026

Overview

Semmelweis University has awarded a contract to Med Gen-Sol Korlátolt Felelősségű Társaság for performing 21-gene genomic testing (Oncotype DX) for early breast cancer patients with HER2 positive, HER2 negative, and hormone receptor positive status. The scope includes sample transport, test performance, result evaluation, recurrence score reporting, receptor validation, and physician consultation, with 200 tests planned over 36 months for a total value of 111.8 million HUF.

Key details

Country
Hungary
Status
Awarded
Category
Services
Procedure
Open
SME suitable
Yes
Published
23 April 2026
Deadline
Closed
Classification (CPV)
Medical practice and related services

Award outcome

Awarded value
HUF 111,800,000
Award date
11 June 2026
Contract period
— → 26 May 2029
Winner
  • Med Gen-Sol Korlátolt Felelősségű Társaság

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    25 June 2026

  2. Contract Notice

    23 April 2026

Contracting authority

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: 21 génes genomikai vizsg. (Oncotype DX) végzése — won by Med Gen-Sol Korlátolt Felelősségű Társaság — Skim